Back to News
Market Impact: 0.2
ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
Source: marketbeat.com
Healthcare & Biotech
ArriVent BioPharma presented Phase I data for ARR-217, a CDH17-targeting antibody-drug conjugate, in heavily pretreated patients with metastatic colorectal cancer. The presentation followed an ESMO late-breaking oral presentation and was delivered during a virtual webinar; the article provides no specific efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
AVBP0.20
More News
- Artiva halts AlloNK development, cuts 94% of workforce
- Universal Health Services falls 3% on legal settlement concerns
- Midterm elections: How affordability and the economy could impact voters
- adar1 capital management buys $53,691 of NextCure stock
- Zura Bio shares jump on Wedbush buy call ahead of trial data
- Why is Artiva Biotherapeutics stock collapsing today?